AMRX Amneal Pharmaceuticals margins

Relative Growth: Rel. Growth: 78

Relative Strength: Rel. Strength: 92

Relative Valuation: Rel. Valuation: 73

Relative Profitability: Rel. Profitability: 56

Gross margin

39.3%

Operating margin

14.6%

EBITDA margin

18.1%

Net margin

Using the latest TTM figures, Amneal Pharmaceuticals shows a gross margin of 39.3%, an operating margin of 14.6%, an EBITDA margin of 18.1%, and a net margin of 5%. Net margin headed the available margin improvements with a 4.9 percentage-point increase, while EBITDA margin dropped by 0.7 percentage points.

AMRX margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Amneal Pharmaceuticals recorded average margins of 36.59% gross, 10.7% operating, 15.82% EBITDA, and -1.54% net. The current gross, operating, EBITDA, and net margins are all above their three-year averages.

AMRX margin expansion

Year-over-year margin changes in percentage points

Amneal Pharmaceuticals's gross margin expanded by 1.6 percentage points, operating margin by 1.4 percentage points, and net margin by 4.9 percentage points, but EBITDA margin contracted by 0.7 percentage points.

Gross margin expansion

1.6pp

Operating margin expansion

1.4pp

EBITDA margin expansion

-0.7pp

Net margin expansion

4.9pp

AMRX Gross margin

Over the last 3 years, Amneal Pharmaceuticals's gross margin averaged 36.59%. The current gross margin of 39.3% is 2.7 percentage points above its three-year average. During this period, gross margin reached a high of 39.3% in Jun 2026 and a low of 34.3% in Dec 2023.

AMRX Operating margin

The average operating margin for Amneal Pharmaceuticals was 10.7% over the last 3 years. Right now, the current operating margin for Amneal Pharmaceuticals is 14.6%, 3.9 percentage points above its three-year average. The operating margin for Amneal Pharmaceuticals moved between 6.3% in Mar 2024 and 14.6% in Jun 2026.

AMRX EBITDA margin

Over the last 3 years, the average EBITDA margin for Amneal Pharmaceuticals was 15.82%. The latest EBITDA margin for Amneal Pharmaceuticals is 18.1%, 2.3 percentage points above its three-year average. Amneal Pharmaceuticals's EBITDA margin ranged from a low of 11.9% in Jun 2024 to a high of 18.8% in Jun 2025.

AMRX Net margin

Over the last 3 years, the average net margin for Amneal Pharmaceuticals was -1.54%. Compared with its three-year average, Amneal Pharmaceuticals's current net margin is 5% and is 6.5 percentage points above its three-year average. Amneal Pharmaceuticals's net margin ranged from a low of -6.9% in Sep 2024 to a high of 5% in Jun 2026.

AMRX margin group comparison

Margins compared with peer-group, industry and sector averages

With a gross margin of 39.3%, AMRX stands below the Healthcare sector and the industry average. Compared to its Healthcare sector average of 68.3%, Amneal Pharmaceuticals's gross margin is 42% lower.

Frequently asked questions

What is Amneal Pharmaceuticals's gross margin?

For the period ending Jun 30, 2026, AMRX recorded a gross margin of 39.3%.

What is Amneal Pharmaceuticals's operating margin?

The current operating margin for AMRX is 14.6% as of Jun 30, 2026.

What is Amneal Pharmaceuticals's EBITDA margin?

As of Jun 30, 2026, AMRX has an EBITDA margin of 18.1%.

What is Amneal Pharmaceuticals's net margin?

As of Jun 30, 2026, AMRX has a net margin of 5%.

What are the average margins of AMRX?

Across the last 3 years, AMRX averaged 36.6% gross, 10.7% operating, 15.8% EBITDA, and -1.5% net.

What are the highest historical margins of AMRX?

Looking back across 5 years, AMRX reached 39.3% gross in Jun 2026, 14.6% operating in Jun 2026, 18.8% EBITDA in Jun 2025, and 5% net in Jun 2026.

What are the lowest historical margins of AMRX?

Over this 5-year history, Amneal Pharmaceuticals's margins fell as low as 34.3% gross in Dec 2023, -6.4% operating in Jun 2022, 11.9% EBITDA in Jun 2024, and -6.9% net in Sep 2024.